The Trump Administration is relying mainly on administrative action to advance its prescription drug pricing agenda because it has not received much help from Congress, but the limitations of that approach are beginning to show.
HHS Secretary Alex Azar, as he unveiled the Administration’s “Blueprint” of policies to lower prices last spring, touted the “power...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?